RE:RE:RE:RE:I hate to say this but.........
Perhaps I should have been more clear and noted that the SDI will be serving a very limited market, with a limited application, assuming that Toraymyxin is approved... which still seems like a long shot to me.
It would seem that this fact is obvious to the equity markets, as the entire market cap is less than 45 mil. Why investors think that the stock is undervalued is beyond me. It is already up 50% from its 12 month lows!
You heard it here first...$1.60 max, post 1 for 5 reverse and USfinancing & listing, with a reasonable $2.00 top end in 2014.